Overview

A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718

Status:
Completed
Trial end date:
2019-10-31
Target enrollment:
Participant gender:
Summary
This study will be conducted to evaluate the AZD5718 pharmacokinetic (PK) doses in order to determine exposure in a new dose range and compare with previous results. This study will include 14 subjects in a single site in United Kingdom. Each subject will be involved in the study for 6 to 7 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Parexel